News and Comments

Aimmune Therapeutics: Oral Peanut desensitization Treatment is Promising

  Wednesday, November 11, 2015

Food allergies are bad, significant, dangerous and growing in the U.S. and the rest of the world. More than 30 million people in the United States and Europe have a food allergy, and more than five million people in the United States and Europe have peanut allergy, including more than two million children.  More...

Exelixis Will Begin Reaping the Fruits

  Tuesday, November 10, 2015

 More...

Incyte Is a Great Biotech Firm

  Saturday, November 07, 2015

To shareholders who were stupefied with an instigated selloff of Incyte’s (INCY) stock today, we say do not get panicky. Nothing is wrong with Incyte, no bad news was announced with any of the firm’s 12 ongoing clinical trials or with its approved drug Jakafi, which demonstrated progressive growth since it was launched.  So, a clever correct move now would be taking advantage and accumulate INCY.  More...

Dyax Acquisition and Biocryst Future

  Tuesday, November 03, 2015

 More...

Another Durable Botulinum Toxin with Many Advantages Over Botox

  Thursday, October 29, 2015

Another Durable, Botulinum Toxin with Many Advantages More...

Cytokinetics Heart Failure Drug Worked

  Tuesday, October 27, 2015

POSITIVE TOP-LINE RESULTS FROM A PHASE 2 TRIAL OF OMECAMTIV MECARBIL IN PATIENTS WITH CHRONIC HEART FAILURE More...

URGENT BREAKING NEWS

  Thursday, October 22, 2015

The FDA issued a warning that hepatitis C treatment Viekira Pak and Technivie can cause serious side effects and serious liver injury, mostly in patients with underlying advanced liver disease.  More...

The Stream of Exelixis Good News is Real

  Thursday, October 22, 2015


 More...

Sarepta Versus Biomarin: Trying to make an Educated Guess

  Monday, October 19, 2015

About Duchenne muscular Dystrophy treatments, bloggers tried to explain the reasons that led the FDA to decide upon reviewing Biomarin’s (BMRN) Duchenne muscular dystrophy (DMD) drug Drisapersen a few weeks earlier than reviewing Sarepta (SRPT) DMD drug Eteplirsen.  More...

Incyte And Merck Agree to Expand Their agreement Regarding their Immunotherapy Combination Drugs

  Tuesday, October 13, 2015

 More...


Recent Postings


Archive


Tags

ImmunoGen (IMGN) Agenus (AGEN) Ariad (ARIA) Sanofi (SNY) AERIE PHARMACEUTICALS Editas (EDIT) Ziofpharm (ZIOP) Telaprevir Agenus (AGEN Akebia Therapeutics (AKAB) Idenix (IDIX) Tysabri Auspex (ASPX) JUNO (JUNO) NEUROCRINE (NBIX) PORTOLA (PTLA) Prolor Biotech (PBTH) Adaptimmune (ADAP) Jazz Pharmaceuticals (JAZZ) Inovio (INO) SERES THERAPEUTICS (MCRB) Rapamune Zerenex Regeneron (REGN) Roche (ROCHE) ARGOS (ARGS) Theravance (THRX) TOKAI (TKAOI) Elan (ELN) Illumina (ILMN) IDERA (IDRA) NEKTAR (NKTR)) NANTKWEST (NK) Human Longevity (HLI) Biocryst (BCRX) Herceptin Bellicum (BLCM) Global Cell Therapeutics (GBT) galapagos (GLPG) Aimmune Therapeutics (AIMT) Vitae Pharmaceuticals (VTAE) ZALTRAP™ Gilead (GILD) ARCA (ABIO) Velcade (bortezomib) Anacor (ANAC) CRISPR Therapeutics (CRSP) Intrexon (XON) OSI (OSIP) Anadys (ANDS) Intermune (ITMN) Ionis (IONS) Galena (GALE) Seattle Genetics (SGEN) Onyx (ONXX) Theravance Bio Pharma (TBPH) Epizyme (EPZM) LEXICON (LXRX) ADVENTRIX (ANX) Mirati Therapeutics (MRTX) Vertex (VRTX) RenenxBio (RGNX) INNOVIVA (INVA) Endometrial Cancer Roche (RHHBY) Xoma (XOMA) Amgen (AMGN) Benlysta (belimumab) Pluristem (PSTI) Trastuzumab-DM1 Alnylam (ALNY) ISIS (ISIS) Human Genome Sciences (HGSI) Dendreon (DNDN) Cytokinetics (CYTK) Micromet (MITI) Sequenom (SQNM) KERYX (KERX) HALOZYME (HALO) Incyte (INCY) Intercept (ICPT) Revlimid (lenolidamide) GUARDIAN HEALTH NOVOCURE (NVCR) ABBVIE (ABBV) SYNTA (SNTA) PTC Therapeutics (PTCT) Bristol-Myers Squibb (BMY) Ridaforolimus Sarepta (SRPT) REGULUS (RGLS) Dynavax (DVAX) MODERNA OncoCyte (OCX) VANDA (VNDA) Valeant Pharmaceuticals International (VRX) AGOS (ARGS) C4 Therapeutics Array Pharmaceuticals (ARRY) KITE (KITE) JOUNCE THERAPEUTICS (JNCE) AstraZeneca (AZN) BIOMARIN (BMRN) Biogen Idec (BIIB) Merck (MRK) SUNESIS PHARMACEUTICALS (SNSS) GlaxoSmithKline (GSK) Spike Therapeutics (ONCE) GlycoMimetics (GLYN) Multiple Myeloma Sanofi (SNA) Prosensa (RNA) Exelixis (EXEL) CEMPRA (CEMP) Advaxis (ADXS) Abbott Laboratories (ABT) Alder Biopharmaceuticals (ALDR) ACADIA (ACAD) Sanofi-Aventis (SAN) Sangamo (SGMO) Genentech Ocular Therapeutix (OCUL) CompuGen (CGEN)